Allergan Dismisses Legal Action Against Jan Marini

IRVINE, CA - Allergan Inc. announced in a press release that it has agreed to dismiss its legal action against Jan Marini Skin Research Inc. (Jan Marini), one of the defendants in Allergan's patent infringement lawsuit pending in the United States District Court for the Central District of California.

The dismissal is based on Jan Marini acknowledging the validity of Allergan's relevant patents covering the use of certain drug substances, such as prostaglandin analogs, to promote eyelash enhancement and also agreeing to cease its distribution of eyelash products containing these ingredients in the US and other countries worldwide where Allergan owns related patents.

As recently announced, Allergan has completed a clinical program with its patented formulation of bimatoprost, a synthetic prostaglandin analog, and will pursue United States Food and Drug Administration approval to market a product to stimulate eyelash growth in the United States.

"We are pleased that Jan Marini has acknowledged that Allergan's US and foreign eyelash growth patents are valid and enforceable and has agreed to cease further distribution of its eyelash growth products," Allergan's Executive Vice President ,Chief Administrative Officer, General Counsel and Secretary Douglas Ingram said.

"Allergan has a significant Intellectual Property estate covering this area. Allergan has sued, or is evaluating suit against, a number of infringers for refusing to respect our Intellectual Property Rights,” he added.

“As evidenced by our ongoing lawsuit against those companies and individuals who have chosen to market unapproved eyelash products containing active pharmaceutical ingredients, Allergan will not idly stand by while others infringe our Intellectual Property Rights," Ingram concluded.